Navidea Biopharmaceuticals Announces Underwritten Sale of Common Stock
DUBLIN, Ohio -- January 30, 2013
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, announced today that it
has priced an underwritten sale of common stock in a transaction led by J.P.
Morgan Asset Management and involving one other institutional investor. In the
offering 1,542,389 shares were sold in an at market transaction at a price of
$3.10 per share for gross proceeds of approximately $4.8 million. The net
proceeds of the financing will be used to fund Navidea’s ongoing operations.
The sale is expected to close on or about February 4, 2013, subject to the
satisfaction of customary closing conditions.
“We are excited that J.P. Morgan Asset Management and another institution,
premier investors in the biotechnology sector, have decided to establish
meaningful positions in Navidea,” said Dr. Mark Pykett, President and CEO of
Navidea. “Through our efforts to build relationships with potential
institutional investors and catalyze interest in Navidea, we were presented
with this targeted opportunity to expand our institutional base with
outstanding investors. We are pleased to be able to capitalize on this
opportunity to strengthen our shareholder base as we look forward to the
approval of our first commercial radiopharmaceutical agent, Lymphoseek.”
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial
Services Inc. (NYSE MKT: LTS), acted as the exclusive underwriter in
connection with the offering. The shares described above are being offered
pursuant to a shelf registration statement (File No. 333-173752) which was
declared effective by the U.S. Securities and Exchange Commission (SEC) on May
9, 2011. A prospectus supplement related to the offering will be filed with
the SEC. When filed with the SEC, copies of the prospectus supplement and the
accompanying base prospectus relating to this offering may be obtained at the
SEC's website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co.
Inc., 58 South Service Road, Suite 160, Melville, NY, Attention: George
Mangione, (631) 270-1611 or GMangione@ladenburg.com.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, the shares in any state or
other jurisdiction which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe
harbor for forward-looking statements made by or on behalf of the Company.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing products and
technologies, anticipated clinical and regulatory pathways, the ability to
obtain, and timing of, regulatory approvals of the Company’s products, the
timing and anticipated results of commercialization efforts, and anticipated
markets for the Company’s products, are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,”
“project,” and similar expressions identify forward-looking statements that
speak only as of the date hereof. Investors are cautioned that such statements
involve risks and uncertainties that could cause actual results to differ
materially from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating losses,
timing, cost and uncertainty of regulatory approvals for its drug candidates,
and market acceptance of its products, reliance on third party manufacturers,
accumulated deficit, future capital needs, uncertainty of capital funding,
dependence on limited product line and distribution channels, competition,
limited marketing and manufacturing experience, risks of development of new
products, and other risks detailed in the Company’s most recent Annual Report
on Form 10-K and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any forward-looking
Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr. VP & CFO
Press spacebar to pause and continue. Press esc to stop.